Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Vancocin Gets Generic Competition

By Drug Discovery Trends Editor | April 11, 2012

NEW YORK (AP) – ViroPharma Inc. said that three companies are now selling low-cost generic versions of its drug Vancocin, an antibiotic that brings in half of ViroPharma’s revenue.

ViroPharma didn’t identify the companies. But Watson Pharmaceuticals Inc. and Akorn Inc. confirmed they received marketing approval for their versions of Vancocin and are launching their equivalents.

ViroPharma reported $288.9 million in revenue from Vancocin, or vancomycin, in 2011. The drug is used to treat diarrhea associated with the bacterium C. difficile and for gastrointestinal infections caused by Staphylococcus aureus. Regulators approved a new label for Vancocin in December that included new data on the drug’s effectiveness and safety as a treatment for C. difficile. The company said it believed the new label would keep competing generics off the market for three years.

ViroPharma said the FDA determined that it is not entitled to any new marketing exclusivity based on the changes to the Vancocin label. The Exton, Pa., company said it will file an injunction in the U.S. District Court for the District of Columbia and ask the court to set aside the approvals of the generic versions of Vancocin.

Watson of Parsippany, N.J. and Akorn of Lake Forest, Ill., are each selling generic vancomycin in two strengths.

Date: April 10, 2012
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50